Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05264727CT.gov Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Type 2 Diabetes Mellitus
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Clinisol 15% (this asset) | Mayo Clinic | Approved | B · 59 |
| Liraglutide | RenJi Hospital | P4 | BBB |
| Semaglutide | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Exenatide | Vivani Medical, Inc | P4 | BBB |
| Cotadutide | AstraZeneca | P2 | BBB |
| Dapagliflozin | Bhavya Bhavya, MD | P4 | BBB |
| Metformin | Myopharm Limited | P4 | BBB |
| Saxagliptin | Nick Giannoukakis, PhD | P4 | BBB |
| Midazolam | Pfizer | P4 | BBB |
+41 more in the Type 2 Diabetes Mellitus cohort
Other indications for Clinisol 15%
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Obesity Disorder | — | P4 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Clinisol 15% in Type 2 Diabetes Mellitus. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/clinisol-15-type-2-diabetes-mellitus
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →